Matches in Wikidata for { <http://www.wikidata.org/entity/Q65371413> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q65371413 description "clinical trial" @default.
- Q65371413 description "ensayu clínicu" @default.
- Q65371413 description "klinisch onderzoek" @default.
- Q65371413 description "клінічне випробування" @default.
- Q65371413 name "A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion" @default.
- Q65371413 name "A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia" @default.
- Q65371413 type Item @default.
- Q65371413 label "A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion" @default.
- Q65371413 label "A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia" @default.
- Q65371413 prefLabel "A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion" @default.
- Q65371413 prefLabel "A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia" @default.
- Q65371413 P1050 Q65371413-1FE0F6BB-416C-4EA2-AC9B-1AEE26E5D805 @default.
- Q65371413 P1050 Q65371413-8A626EB1-6B3C-49CC-805A-2FE35EBFB9F1 @default.
- Q65371413 P1132 Q65371413-2F958376-897C-4A23-BB24-1B51355C30D7 @default.
- Q65371413 P1476 Q65371413-262FE7B2-5B3E-463A-8E60-ED9B9BA223F4 @default.
- Q65371413 P17 Q65371413-0631E385-3689-42D3-AF87-D40AA14592A6 @default.
- Q65371413 P17 Q65371413-28E37CB0-26B7-4761-BFA8-828D7F4DF645 @default.
- Q65371413 P17 Q65371413-5B5CD95B-E3A8-4E10-A161-C5C2835B8456 @default.
- Q65371413 P17 Q65371413-9A16C6E9-C063-4687-99D4-D8848F4660CB @default.
- Q65371413 P17 Q65371413-A327ADC6-6E0A-4250-99B2-96ABB75E76F2 @default.
- Q65371413 P17 Q65371413-A84EB731-8255-4404-9DB8-46FF8700183D @default.
- Q65371413 P17 Q65371413-CD49923D-617A-4D82-B70B-7D9347ED9B8E @default.
- Q65371413 P17 Q65371413-DAFCA8D8-FDA3-443F-B0D7-BEA90FD64A07 @default.
- Q65371413 P17 Q65371413-DE5E64D1-DA7A-492D-8E8C-B04F2177D244 @default.
- Q65371413 P2899 Q65371413-DAEB942A-EEAC-41EC-86A6-4662E636C3B1 @default.
- Q65371413 P3098 Q65371413-4C0E1199-12FA-4EEB-BA72-93AAAC06F86E @default.
- Q65371413 P31 Q65371413-8FFEE25B-D70C-4B31-9B8E-A4E72A1F9DEA @default.
- Q65371413 P580 Q65371413-A8ED3BDC-C1B3-45B0-9791-E52705BCB1AC @default.
- Q65371413 P582 Q65371413-71175EFC-2BE3-4F5F-92A7-B9B1583120FF @default.
- Q65371413 P6099 Q65371413-15F84EC2-78BC-459F-BD7F-E9DBE5CF3D20 @default.
- Q65371413 P8363 Q65371413-778D68D8-FCE3-40A0-B32B-062E5D22F7D9 @default.
- Q65371413 P1050 Q208414 @default.
- Q65371413 P1050 Q29496 @default.
- Q65371413 P1132 "+145" @default.
- Q65371413 P1476 "An Open-label, Single Arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With 17p Deletion (RESONATE™-17)" @default.
- Q65371413 P17 Q145 @default.
- Q65371413 P17 Q16 @default.
- Q65371413 P17 Q183 @default.
- Q65371413 P17 Q30 @default.
- Q65371413 P17 Q31 @default.
- Q65371413 P17 Q34 @default.
- Q65371413 P17 Q408 @default.
- Q65371413 P17 Q43 @default.
- Q65371413 P17 Q664 @default.
- Q65371413 P2899 "+18" @default.
- Q65371413 P3098 "NCT01744691" @default.
- Q65371413 P31 Q30612 @default.
- Q65371413 P580 "2013-01-01T00:00:00Z" @default.
- Q65371413 P582 "2014-06-01T00:00:00Z" @default.
- Q65371413 P6099 Q42824440 @default.
- Q65371413 P8363 Q78089383 @default.